Traitement du diabète de type 2 : l'exénatide à libération prolongée

This review presents exenatide prolonged-release (Bydureon®) main pharmacokinetics and pharmacokinetics properties and results from randomized clinical trials, a GLP-1R agonist approved for T2D treatment and marketed in the US and approved in Europe where it is available in some countries and expected to be available in France.